CEO in Danish Nuevolution, Alex Gouliaev, credits his employees for Amgen's offer to acquire the company for USD 167 million. He hopes that he and most staff members will continue their work under the new leadership, which is to speed up development in the Danish company.
US drug group Amgen has offered to acquire its Danish partner Nuevolution for USD 167 million - an increase by 169 percent relative to Nuevolution's closing price Tuesday this week. The board recommends that the shareholders accept the offer.
Danish pharmaceutical company Azanta has appointed a new CEO. His main task is to pave the way to the European market for Azanta's drug, which the company already launched in some countries by use of untraditional methods.
Bavarian Nordic has enough money for financing a comprehensive phase III study with its RSV vaccine for approximately USD 100 million alone - unless an attractive partner expresses interest before summer.
For the first time ever, Gubra's gross profit exceeded DKK 100 million in 2018. In addition, the Danish contract research organization expanded the workforce with 50 people. CEO Henrik Blou ascribes the development to the company's combination of contract research services and its own research projects.
Danish Xellia Pharmaceuticals has signed a contract with newly established US non-profit organization Civica Rx, which opens the door to 500 US hospitals.
Danish Symphogen's previous strategy did not convince the investors, says CEO Martin Olin. He is happy that shareholders like Novo Nordisk and Sunstone Capital continue to support the company but also acknowledges that long-term shareholders deserve an opportunity to exit.
Drug groups that develop medicines based on research from universities and hospitals should give more back to society, say three Danish parties. Minister for Higher Education and Science, Tommy Ahlers, and the Danish Association of the Pharmaceutical Industry (Lif) calls the proposal a surtax for the industry.
Emmanuel Dulac has replaced Britt Meelby Jensen as CEO of Zealand Pharma, but the company still needs to find the successor of former CFO, Mats Blom. Dulac himself leads the recruitment process and expects to appoint a new manager in a few weeks.
While a number of international companies in the past five years have reinvested an increasingly larger part of their revenue in R&D, the opposite trend is evident at two of Denmarks largest pharmaceutical companies. But new strategies may change this fact in the coming years.
Roche has been quick to make three agreements with Danish educational institutions. The goal is to provide students with greater insights into the opportunities offered by the industry while the pharmaceutical company hopes to get one step ahead in the race for future talent.
General Manager of the Danish division of Roche Diagnostics has been appointed GM in the Netherlands. Roche denies the manager’s short-term exit from Denmark, saying she will continue her work in Copenhagen on an ”interim” basis.
A long-awaited label expansion has made it easier for Veloxis to sell its product, but the impact will not truly manifest before a later time, says the company's CEO following an interim report showing a 96 percent growth in sales.
Jens Bager, Chairman of the board in Ambu, confirms that the company has fired CEO Lars Marcher to bring in more international competences for the global launch of a new range of endoscopes.
Danish allergy group ALK recently presented the best Q1 interim report in the company's history. However, the CEO anticipates red numbers in the annual report as ALK continues to invest in the future.
Newly-founded ROS Therapeutics' lead candidate showed disappointing pre-clinical results. The company's future now hangs by a thread.
After less than two years of existence, Danish Radiobotics has received DKK 10 million (USD 1.5 million) from a group of new rich investors to file for approval of the company's product in the Europe and the US.
EU has granted EUR 1.83 million (USD 2.06 million) to Danish medtech company Cercare Medical to develop and commercialize a new technology using artificial intelligence to read and understand MRI- and CT scan images.
Contract research organizations all over the world experience unprecedented growth rates, especially because more and more drug groups bring in external innovation from biotech companies.
Novo Nordisk and its rivals support a US proposal to criminalize discounts to middlemen in the public health channel Medicare from 2020. However, Novo's CEO, Lars Fruergaard Jørgensen, warns that the initiative will create a gap somewhere else in the budget.
Danish e-health company Klikkit has received DKK 2.5 million (USD 370,000) from two business angels for a large-scale launch of the company's app that helps patients change habits and remember their medicine.
Danish drug group Lundbeck is starting to act up to its strategy of pursuing acquisitions and partnerships, says CEO Deborah Dunsire, who reports increased cash balance despite generic competition and the largest dividend payout ever.
It was not just the opportunity to take over a candidate in phase II that made Lundbeck pay up to DKK 2.7 billion for a US company this week. It was mainly the chance to improve the Danish drug group's opportunity to develop brand-new drugs, says CEO Deborah Dunsire.
Although Victoza yielded disappointing results in first quarter, and Novo Nordisk's GLP-1 portfolio is generally under pressure, CEO Lars Fruergaard Jørgensen denies that the segment is subject to increased competition or price pressure. The company has no influence on the underlying reasons, he says.
Danish Chemometec joins forces with research team from University of Copenhagen to develop a method to diagnose cancer early. The project is still "on a very early stage" but can potentially pave the way to a whole new business area for the medtech firm.
